Eagle Pharmaceuticals Inc. (EGRX)

57.60
NASDAQ : Health Technology
Prev Close 59.19
Day Low/High 57.38 / 59.67
52 Wk Low/High 36.03 / 70.13
Avg Volume 140.20K
Exchange NASDAQ
Shares Outstanding 14.86M
Market Cap 879.68M
EPS 2.20
P/E Ratio 19.77
Div & Yield N.A. (N.A)

Short Interest Decreases By 13.8% For EGRX

The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 463,296 share decrease in total short interest for Eagle Pharmaceuticals, Inc. , to 2,903,619, a decrease of 13.76% since 04/28/2017.

Notable Monday Option Activity: EGRX, RRGB, LE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Eagle Pharmaceuticals, Inc. , where a total volume of 2,929 contracts has been traded thus far today, a contract volume which is representative of approximately 292,900 underlying shares (given that every 1 contract represents 100 underlying shares).

Eagle Pharmaceuticals Appoints Pete A. Meyers As Chief Financial Officer

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") announced that Pete A.

Eagle Pharmaceuticals, Inc. To Present At Bank Of America Merrill Lynch 2017 Health Care Conference

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the Bank of America Merrill Lynch 2017 Health Care Conference...

Eagle Pharmaceuticals, Inc. Reports First Quarter 2017 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced its financial results for the three months ended March 31, 2017.

Eagle Pharmaceuticals, Inc. To Discuss First Quarter 2017 Financial Results On May 8, 2017

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) announced today that the Company will release its 2017 first quarter financial results on Monday, May 8, 2017, before the market opens.

Eagle Pharmaceuticals, Inc. To Present At 42nd Annual Deutsche Bank Health Care Conference

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference as...

Eagle Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Eagle Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $86.25, changing hands for $87.12/share.

FDA Grants Priority Review For Eagle Pharmaceuticals' Ryanodex NDA For The Treatment Of Exertional Heat Stroke

Eagle Pharmaceuticals (Nasdaq:EGRX) ("Eagle" or "the Company") announced today that their 505(b)(2) New Drug Application (NDA) for Ryanodex® (dantrolene sodium) for the treatment of exertional heat stroke (EHS) has...

Eagle Pharmaceuticals Announces Three New Patents Issued For Bendeka

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that three additional patents have been issued related to Bendeka by the United States Patent and Trademark Office (USPTO).

18.9% of FTXH Holdings Seeing Recent Insider Buys

A look at the weighted underlying holdings of the First Trust Nasdaq Pharmaceuticals ETF (FTXH) shows an impressive 18.9% of holdings on a weighted basis have experienced insider buying within the past six months. START SLIDESHOW:10 ETFs With Stocks That Insiders Are Buying » Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals Appoints Richard A. Edlin To Board Of Directors

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that its Board of Directors has approved the appointment of Richard A.

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2016 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced its financial results for the three- and twelve-months ended December 31, 2016.

Eagle Pharmaceuticals' Pemetrexed NDA Accepted For Filing By The FDA

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that the 505(b)(2) New Drug Application (NDA) for its novel Pemetrexed Injection, 25 mg/mL has been accepted for filing by the U.

Eagle Pharmaceuticals Announces 11th Patent Issued For Bendeka

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that the United States Patent and Trademark Office (USPTO) has issued an 11 th patent related to Bendeka.

Eagle Pharmaceuticals Announces New Patents Issued For Bendeka

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that four additional patents have been issued related to Bendeka by the United States Patent and Trademark Office (USPTO).

Eagle Pharmaceuticals, Inc. To Discuss Fourth Quarter And Full Year 2016 Financial Results On March 1, 2017

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) announced today that the Company will release its 2016 fourth quarter and full year financial results on Wednesday, March 1, 2017, before the market...

Eagle Pharmaceuticals To Present At 2017 RBC Capital Markets Global Healthcare Conference

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, David Pernock, President and Chief Commercial Officer, and David Riggs, Chief Financial Officer, will present at the...

Three Health-Care Growth Plays

Three Health-Care Growth Plays

Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.

Eagle Pharmaceuticals Completes NDA Submission For Ryanodex For Exertional Heat Stroke To FDA

Eagle Pharmaceuticals Completes NDA Submission For Ryanodex For Exertional Heat Stroke To FDA

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that it has completed the submission of its 505(b)(2) New Drug Application (NDA) for Ryanodex® for the treatment of exertional heat...

Eagle Pharmaceuticals is Now Oversold (EGRX)

Eagle Pharmaceuticals is Now Oversold (EGRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Eagle Pharmaceuticals To Present At J.P. Morgan 35th Annual Healthcare Conference

Eagle Pharmaceuticals To Present At J.P. Morgan 35th Annual Healthcare Conference

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the J.

Eagle Pharmaceuticals' Pemetrexed NDA Submitted For Review

Eagle Pharmaceuticals' Pemetrexed NDA Submitted For Review

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that the 505(b)(2) New Drug Application (NDA) for its novel pemetrexed drug product has been submitted to the U.

Eagle Pharmaceuticals Announces David Pernock As President And Chief Commercial Officer

Eagle Pharmaceuticals Announces David Pernock As President And Chief Commercial Officer

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced that David Pernock will join Eagle as President and Chief Commercial Officer, effective January 2017.

Eagle Pharmaceuticals Reports Positive Results From Pivotal Animal Study Supporting The Efficacy Of RYANODEX For Exertional Heat Stroke

Eagle Pharmaceuticals Reports Positive Results From Pivotal Animal Study Supporting The Efficacy Of RYANODEX For Exertional Heat Stroke

Eagle Pharmaceuticals ("Eagle" or the "Company") (NASDAQ:EGRX) today announced positive results from its pivotal animal study conducted under the Animal Rule 1, for Ryanodex® for the treatment of Exertional Heat Stroke...

Eagle Pharmaceuticals To Present At Piper Jaffray 28th Annual Healthcare Conference

Eagle Pharmaceuticals To Present At Piper Jaffray 28th Annual Healthcare Conference

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (NASDAQ:EGRX) today announced that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the Piper Jaffray...

Eagle Pharmaceuticals Signs Definitive Agreement To Acquire Arsia Therapeutics Marking Entry Into Biosimilar Market

Eagle Pharmaceuticals Signs Definitive Agreement To Acquire Arsia Therapeutics Marking Entry Into Biosimilar Market

Eagle Pharmaceuticals ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that it has signed a definitive agreement to acquire Arsia Therapeutics ("Arsia"), an early-stage biotechnology firm with proprietary...

Eagle Pharmaceuticals Initiates Rolling Submission Of NDA For Ryanodex In Exertional Heat Stroke

Eagle Pharmaceuticals Initiates Rolling Submission Of NDA For Ryanodex In Exertional Heat Stroke

Eagle Pharmaceuticals ("Eagle" or the "Company") (NASDAQ: EGRX) today announced that the Company has initiated the rolling submission of its New Drug Application (NDA) and filed the first part of the application to the U.

Eagle Pharmaceuticals To Present At Jefferies 2016 London Healthcare Conference

Eagle Pharmaceuticals To Present At Jefferies 2016 London Healthcare Conference

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) today announced that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the Jefferies 2016...

Eagle Pharmaceuticals, Inc. Reports Third Quarter 2016 Results

Eagle Pharmaceuticals, Inc. Reports Third Quarter 2016 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced its financial results for the three- and nine-months ended September 30, 2016.

TheStreet Quant Rating: C+ (Hold)